5,460 reports of this reaction
1.7% of all DICLOFENAC SODIUM TOPICAL reports
#9 most reported adverse reaction
PEMPHIGUS is the #9 most commonly reported adverse reaction for DICLOFENAC SODIUM TOPICAL, manufactured by Aurobindo Pharma Limited. There are 5,460 FDA adverse event reports linking DICLOFENAC SODIUM TOPICAL to PEMPHIGUS. This represents approximately 1.7% of all 323,576 adverse event reports for this drug.
Patients taking DICLOFENAC SODIUM TOPICAL who experience pemphigus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PEMPHIGUS is a less commonly reported adverse event for DICLOFENAC SODIUM TOPICAL, but still significant enough to appear in the safety profile.
In addition to pemphigus, the following adverse reactions have been reported for DICLOFENAC SODIUM TOPICAL:
The following drugs have also been linked to pemphigus in FDA adverse event reports:
PEMPHIGUS has been reported as an adverse event in 5,460 FDA reports for DICLOFENAC SODIUM TOPICAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
PEMPHIGUS accounts for approximately 1.7% of all adverse event reports for DICLOFENAC SODIUM TOPICAL, making it a notable side effect.
If you experience pemphigus while taking DICLOFENAC SODIUM TOPICAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.